表紙
市場調查報告書
商品編碼
635918

全球C-反應性蛋白質檢驗市場:化驗類別,各用途,各地區趨勢 - 成長,趨勢,預測

C-reactive Protein Testing Market - Growth, Trends, and Forecast (2019 - 2024)

出版日期: | 出版商: Mordor Intelligence Pvt Ltd | 英文 115 Pages | 商品交期: 2-3個工作天內

價格

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

  • 全貌
  • 簡介
  • 目錄
簡介

本報告提供全球C-反應性蛋白質檢驗市場相關調查,彙整市場概要和化驗類別,各用途,各地區趨勢,及加入此市場的主要企業的簡介等資料。

第1章 簡介

第2章 調查方法

第3章 摘要整理

第4章 主要推論

第5章 市場概要

  • 目前市場方案
  • 波特五力分析

第6章 市場趨勢

  • 推動市場的要素
  • 阻礙市場的要素
  • 機會
  • 主要課題

第7章 市場區隔

  • 化驗類別
    • 酵素免疫吸附法(ELISA)
    • 化學冷光免疫檢測(CLIA)
    • 免疫比濁檢驗
    • 其他
  • 各用途
    • 糖尿病
    • 類風濕性關節炎
    • 心血管疾病
    • 發炎性腸道疾病
    • 癌症
    • 其他
  • 各地區
    • 北美
    • 歐洲
    • 亞太地區
    • 中東·非洲
    • 南美

第8章 競爭環境

  • 合併·收購分析
  • 協定,聯合,聯盟
  • 新產品上市

第9章 主要加入企業

  • Abaxis
  • Abbott
  • Danaher
  • Hoffmann-La Roche Ltd
  • Laboratory Corporation of America Holdings
  • Merck KGaA
  • Quest Diagnostics
  • Randox Laboratories Ltd
  • Siemens Healthineers
  • Thermo Fisher Scientific, Inc.

第10章 市場未來

目錄
Product Code: 60431

Market Overview

The major factors propelling the growth of the C-reactive protein testing market include the rise in prevalence of inflammatory disorders, the increasing global incidence of endometriosis in women, rise in funding toward the technological advancement in diagnostics, and rise in the adoption of point-of-care devices.

Chronic inflammation is found to be the primary contributing factor involved in multiple chronic diseases, such as rheumatoid arthritis, lupus, ulcerative colitis, Crohn's disease, and others. In developed countries, such as the United States, a significantly large section of the population, approximately 1.6 million people are affected by rheumatoid arthritis and nearly 18 million people are affected globally.

During the infectious state of the inflammatory disease, the CRP levels rise rapidly within the body and peak up to levels of 350-400 mg/L after 48 hours. When the inflammation decreases, the CRP levels fall, making it a highly useful marker for monitoring the activity of diseases. Therefore, a regular standardization of measurement techniques and reporting improve the utility of CRP in regular clinical practice. CRP has multiple applications within in vitro and in vivo, for the development of potential new compounds for inflammatory diseases. Thus, the rising prevalence of inflammatory diseases is among the foremost factors driving the market studied.

Furthermore, there is also an increase in funds provided to academic research institutions and individual researchers that is expected to boost market growth. Moreover, various initiatives by international bodies, such as WHO and NIH for the prevention and treatment of chronic disorders, such as cardiovascular diseases and cancer are anticipated to promote the growth of the market.

Scope of the Report

As per the scope of the report, C-reactive protein (CRP) is one of the highly useful markers of inflammation in the body, which is produced by cells in the liver. C-reactive protein tests are the blood tests that measure the levels of C-reactive protein. These proteins are produced by the liver and its level increase when there is inflammation in the body. These tests help to identify and keep track of diseases that cause inflammation, such as certain types of cancers, cardiovascular diseases, arthritis, etc.

Key Market Trends

Cardiovascular Disease is the Largest Segment Under Application that is Expected to Grow in the Forecast Period

Cardiovascular disorders account for the largest share in terms of adoption. Due to the high prevalence of cardiovascular diseases, there is an urgent need for developing a quick and effective method for diagnosis. So, C-reactive protein can be an indicator for the detection of CVD as there is a development of atherosclerosis, which is the laying down of cholesterol inside the blood vessel walls that create inflammation within the vessel walls. Hence, in patients suffering from CVD, there is a higher level of CRP. Therefore, the CRP assays to detect lower levels of CRP, which are sensitive. Hence, the high incidence rate of cardiovascular diseases is expected to encourage researchers to undertake investigational studies in CRC for cardiovascular disorders.

North America has Been Reported with the Largest Growth and is Expected to Follow the Same Trend Over the Forecast Period

North America has dominated the market with the largest revenue share. The factors that are likely to be responsible for the dominance of this segment are the presence of established players, technological advancements, and well-established healthcare infrastructure. Also due to effective government policies, a huge base of multinational companies, as well as high awareness among the people for testing and testing devices in healthcare, the market is expected to grow in the upcoming years.

Competitive Landscape

The major players are seen forming strategic partnerships with other market players to expand their product portfolios. They are also looking to expand their R&D, distribution, and management facilities to gain a competitive edge in the market.

Reasons to Purchase this report:

  • The market estimate (ME) sheet in Excel format
  • Report customization as per the client's requirements
  • 3 months of analyst support

Table of Contents

1 INTRODUCTION

  • 1.1 Study Deliverables
  • 1.2 Study Assumptions
  • 1.3 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Rise in Prevalence of Inflammatory Disorders
    • 4.2.2 Increasing Global Incidence of Endometriosis in Women
    • 4.2.3 Rise in Funding toward the Technological Advancement in Diagnostics
    • 4.2.4 Rise in the Adoption of Point-of-care Devices
  • 4.3 Market Restraints
    • 4.3.1 Lack of Public Awareness
    • 4.3.2 Availability of Alternative Treatments with Higher Accuracies
  • 4.4 Porter's Five Forces Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION

  • 5.1 By Assay Type
    • 5.1.1 Enzyme-linked Immunosorbent Assay (ELISA)
    • 5.1.2 Chemiluminescence Immunoassay (CLIA)
    • 5.1.3 Immunoturbidimetric Assay
    • 5.1.4 Other Assay Types
  • 5.2 By Application
    • 5.2.1 Diabetes
    • 5.2.2 Rheumatoid Arthritis
    • 5.2.3 Cardiovascular Disease
    • 5.2.4 Inflammatory Bowel Disease
    • 5.2.5 Cancer
    • 5.2.6 Other Applications
  • 5.3 Geography
    • 5.3.1 North America
      • 5.3.1.1 US
      • 5.3.1.2 Canada
      • 5.3.1.3 Mexico
    • 5.3.2 Europe
      • 5.3.2.1 Germany
      • 5.3.2.2 UK
      • 5.3.2.3 France
      • 5.3.2.4 Italy
      • 5.3.2.5 Spain
      • 5.3.2.6 Rest of Europe
    • 5.3.3 Asia-Pacific
      • 5.3.3.1 China
      • 5.3.3.2 Japan
      • 5.3.3.3 India
      • 5.3.3.4 Australia
      • 5.3.3.5 South Korea
      • 5.3.3.6 Rest of Asia-Pacific
    • 5.3.4 Middle East & Africa
      • 5.3.4.1 GCC
      • 5.3.4.2 South Africa
      • 5.3.4.3 Rest of Middle East & Africa
    • 5.3.5 South America
      • 5.3.5.1 Brazil
      • 5.3.5.2 Argentina
      • 5.3.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 Abaxis Inc. (Zoetis)
    • 6.1.2 Abbott Laboratories
    • 6.1.3 Beckman Coulter Inc. (Danaher Corporation)
    • 6.1.4 F. Hoffmann-La Roche AG
    • 6.1.5 Laboratory Corporation of America Holdings
    • 6.1.6 Merck KGaA
    • 6.1.7 Quest Diagnostics
    • 6.1.8 Randox Laboratories Ltd
    • 6.1.9 Siemens Healthineers
    • 6.1.10 Thermo Fisher Scientific Inc.

7 MARKET OPPORTUNITIES AND FUTURE TRENDS